NASDAQ · Biotechnology

AVEO Pharmaceuticals / AVEO Oncology (AVEO)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered

Ratings unavailable

$15.00Price unavailableCached market snapshot

Market cap—

Cash—

Quarterly burn$0

Pipeline assets1

Short float2.4%

Latest coverage

News & Press Releases

External sources

Jul 22, 2026

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer PatientsBusiness Wire

Jun 30, 2026

AVEO Oncology Announces Succession PlanPR Newswire

Company profile

About AVEO Pharmaceuticals / AVEO Oncology

AVEO Pharmaceuticals / AVEO Oncology is a biotechnology company in the healthcare sector.

Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.